Spray Drying of mRNA Lipoplexes to Produce an Inhalable Dry Powder Formulation for mRNA Therapeutics
Introduction
- Many respiratory pathogens enter the body through the respiratory tract, the lungs and the mucosal immune system are promising targets for therapeutic interventions.
- Liquid vaccines face the risk of chemical degradation and physical instability
-> Solid formulations can secure stability without challenging storage conditions. Since spray drying offers continuous manufacturing with high yields, we chose spray drying as production technic.
Objective
This study aimed to produce a dry powder formulation with intact mRNA and a satisfactory aerodynamic performance.
-> To achieve that goal, we aimed to find the optimal spray drying parameters. Then, we assessed and optimised the aerodynamic performance.
Determining the Optimal Outlet Temperature
Why?
During spray drying, mRNA lipoplexes have to withstand several stress factors, especially thermal stress. The maximum temperature a product is subjected to during this process is the outlet temperature.
-> What is outlet temperature at which the mRNA remains intact?
How?
- Spray drying firefly luciferase mRNA lipoplexes in mannitol matrix at:
- inlet temperature 120 °C
- outlet temperature 50, 60, 70 °C
- Transfecting spray dried powder into CALU-3 und A549 cells
- DLS measurements to analyse z-average and zetapotential
Outcome?
- Best transfection efficiency at an outlet temperature of 50 °C
- Z-Average and zetapotential show stable nanoparticles within the desired size range
Aerodynamic Performance
Why?
High Fine Particle Fraction (FPF) and low residue in the capsules are requirements for a satisfactory Aerodynamic Performance.
-> How is the aerodynamic performance of the spray dried formulation itself?
How?
- RS01 Inhaler, 5 capsules, 20 mg each, 80 l/min
- Next Generation Impactor
Outcome?
- FPF of 35%
- ca. 20% of powder remaining in the capsules
→Improvement necessary
Improving Aerodynamic Performance
Sweeper crystals
Why?
Sweeper crystals are intended to sweep the capsules’ inner surface clean of remaining powder, allowing the powder to follow the air stream out of the capsule
-> Are sweeper crystals able to help the powder out of the capsule?
How?
- As sweeper crystals four lactose qualities were chosen: InhaLac70, 120, 180, 251
- Blending spray dried powder + lactose sweeper crystals in a turbulamixer (weight ratio 2 + 1)
Outcome?
- In our blends, sweeper crystals…
- did not reduce remaining powder in the capsules
- did not significantly improve the FPF
- facilitated (especially INH70) capsule filling with similar FPF
-> In this study, sweeper crystals did not cause a significant improvement of FPF.
-> Next step: increase dispersibility by adding leucine
See the full poster on “Lipoplexes mRNA Therapeutics” here
(click the picture to download the poster)
Source: MEGGLE poster “Lipoplexes mRNA Therapeutics”, MEGGLE Excipients and the University of Kiel have joined forces to shed light on this interesting topic, Jana Schembera, Ricarda Leister, Constanze Müller, Regina Scherließ
Do you need more information or a sample of MEGGLE excipients?